Abstract
Pefloxacin, which has been shown to have a high in vitro activity against Salmonella spp., was compared to cotrimoxazole in the treatment of typhoid fever in adults. In a prospective, randomized trial, 42 patients with bacteriologically documented typhoid fever received either 400 mg pefloxacin b.i.d. or 160/800 mg cotrimoxazole b.i.d. Duration of treatment was 14 days in both groups. All patients were cured without experiencing a relapse or becoming a salmonella carrier. Apyrexia and resolution of digestive and neurological symptoms were obtained in a significantly shorter time with pefloxacin than with cotrimoxazole. Pefloxacin was well tolerated and more effective than cotrimoxazole in the treatment of typhoid fever.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Drug Combinations / pharmacology
-
Drug Combinations / therapeutic use
-
Female
-
Humans
-
Male
-
Norfloxacin / analogs & derivatives*
-
Norfloxacin / pharmacology
-
Norfloxacin / therapeutic use
-
Paratyphoid Fever / drug therapy*
-
Pefloxacin
-
Prospective Studies
-
Random Allocation
-
Salmonella paratyphi A / drug effects
-
Salmonella paratyphi A / isolation & purification
-
Salmonella paratyphi B / drug effects
-
Salmonella paratyphi B / isolation & purification
-
Salmonella typhi / drug effects
-
Salmonella typhi / isolation & purification
-
Sulfamethoxazole / pharmacology
-
Sulfamethoxazole / therapeutic use*
-
Trimethoprim / pharmacology
-
Trimethoprim / therapeutic use*
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Typhoid Fever / drug therapy*
Substances
-
Drug Combinations
-
Pefloxacin
-
Trimethoprim, Sulfamethoxazole Drug Combination
-
Trimethoprim
-
Sulfamethoxazole
-
Norfloxacin